SVRA (Savara) PB Ratio: 6.67 (As of Jul. 13, 2026) — 239% Above Median


SVRA Savara Inc SVRA
19 GF Score
Price $5.73
! 3 Warning Signs
View Full Analysis

What is Savara PB Ratio?

Savara SVRA -4.98% 19 PB Ratio is 6.67 as of Jul. 13, 2026, which is 239% above its 10-year median of 1.97. GuruFocus rates SVRA with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 1,231 Biotechnology companies, Savara ranks worse than 78.31% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-13), Savara's share price is $5.73. Savara's Book Value per Share for the quarter that ended in Mar. 2026 was $0.86. Hence, Savara's PB Ratio of today is 6.67.

Warning Sign:

Savara Inc stock PB Ratio (=7.02) is close to 5-year high of 7.02.

The historical rank and industry rank for Savara's PB Ratio or its related term are showing as below:

SVRA' s PB Ratio Range Over the Past 10 Years
Min: 0.24   Med: 1.97   Max: 8.2
Current: 6.66

During the past 13 years, Savara's highest PB Ratio was 8.20. The lowest was 0.24. And the median was 1.97.

SVRA's PB Ratio is ranked worse than
78.31% of 1231 companies
in the Biotechnology industry
Industry Median: 2.93 vs SVRA: 6.66

During the past 12 months, Savara's average Book Value Per Share Growth Rate was 0.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 1.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -4.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Savara was 86.80% per year. The lowest was -62.90% per year. And the median was -32.40% per year.

Back to Basics: PB Ratio


Savara  (NAS:SVRA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Savara PB Ratio Related Terms


Savara PB Ratio Historical Data

* Premium members only.

The historical data trend for Savara's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Savara PB Ratio Chart

Savara Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.98 1.64 4.63 3.09 6.07

Savara Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.24 3.27 6.54 6.07 6.36

SVRA vs SPTX, EYPT, MNKD: PB Ratio Comparison

For the Biotechnology subindustry, Savara's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savara PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savara's PB Ratio distribution charts can be found below:

* The bar in red indicates where Savara's PB Ratio falls into.


SVRA
19GF Score
Savara Inc SVRA
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Savara PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Savara's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=5.73/0.859
=6.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 6.67 mean?
Savara (SVRA) has a PB Ratio of 6.67 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Savara and its competitors. This is 239% above median its historical median of 1.97. Over the past decade, Savara's PB Ratio has ranged from 0.24 to 8.20. According to the industry distribution chart, Savara ranks #964 out of 1231 companies in the Biotechnology industry, placing it in the top 78.3%.
Is Savara's PB Ratio too high?
Savara's current PB Ratio of 6.67 is 239% above median its 10-year median of 1.97. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 8.20. The Biotechnology industry median PB Ratio is 2.93. Savara's value of 6.67 is 127.6% above this industry median. Based on the distribution chart, Savara ranks #964 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Savara has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Savara's PB Ratio compare to SPTX and EYPT?
According to the Biotechnology industry distribution chart, Savara ranks #964 out of 1231 companies for PB Ratio. This places Savara in the lower half of its industry. The industry median PB Ratio is 2.93. Savara's value of 6.67 is 127.6% above this benchmark. Historically, Savara's own PB Ratio has ranged from 0.24 to 8.20 over the past decade. While the company's 10-year median is 1.97 vs. the industry median of 2.93, Savara has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Savara's current PB Ratio of 6.67 is 127.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Savara and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Savara's current PB Ratio is 6.67, which is 239% above median its own 10-year median of 1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Savara stock overvalued right now?
Savara (SVRA) has a current PB Ratio of 6.67. The current PB Ratio is 6.67, which is 239% above median its 10-year median of 1.97 and 127.6% above the Biotechnology industry median of 2.93. Savara's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Savara (SVRA), the current PB Ratio is 6.67 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Savara Business Description

Other Exchanges YB4P:Germany
Address 1717 Langhorne Newtown Road, Suite 300, One Summit Square, Langhorne, PA, USA, 19047
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
19GF Score

Get the complete analysis for SVRA

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.73
Price